FDA advisory panel votes to recommend allowing six unproven peptides for compounding pharmacies

Published Aug 3, 07:06 PM UTC

An FDA advisory panel voted to recommend adding six unproven peptides to the list of custom drugs compounding pharmacies can sell, despite prior bans over safety and efficacy concerns. Health Secretary Robert F. Kennedy Jr., a peptides advocate, added eight new members to the panel before the vote, six of whom run clinics offering these chemicals. Proponents argue that thousands already use black market peptides and need safer access, while FDA scientists warn of lacking clinical trial data and potential harmful immune reactions. The vote is a recommendation but approval appears likely, raising fears of a 'Pandora's box' of untested drugs entering the market. Critics see this as part of a broader push to bypass FDA evidence standards in the wellness-focused telehealth era.